Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Phase 2 Study of Multiple Subcutaneous Doses of LY2439821, An Anti-IL-17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis in Two Populations: Naive to Biologic Therapy or Inadequate Responders to Tumor Necrosis Factor Alpha Inhibitors. 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP) Genovese, M. C., Greenwald, M. W., Cho, C. S., Berman, A., Jin, L., Cameron, G., Xie, L., Braun, D., Banerjee, S., Warner, L. WILEY-BLACKWELL. 2011: S1017–S1017
View details for Web of Science ID 000297621503171